Published in Clin Dev Immunol on August 26, 2012
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study (Optimal) | NCT02717949
Molecular and cytogenetic characterization of expanded B-cell clones from multiclonal versus monoclonal B-cell chronic lymphoproliferative disorders. Haematologica (2014) 0.84
Hepatitis C Associated B-cell Non-Hodgkin Lymphoma: Clinical Features and the Role of Antiviral Therapy. J Clin Transl Hepatol (2015) 0.82
Liver fibrosis occurs through dysregulation of MyD88-dependent innate B-cell activity. Hepatology (2015) 0.80
Waldenström macroglobulinemia in hepatitis C: case report and review of the current literature. Case Rep Oncol Med (2014) 0.76
Secondary cutaneous marginal zone B-cell lymphoma presenting as lipoatrophy in a patient with hepatitis C. J Dermatol Case Rep (2014) 0.76
Benign and Malignant Hematological Manifestations of Chronic Hepatitis C Virus Infection. Int J Prev Med (2014) 0.75
Successful and Safe Long-Term Standard Antiviral Therapy in a Patient with "Explosive" Immune Response in Course of HCV-Related Liver Cirrhosis. Int J Mol Sci (2015) 0.75
Splenic marginal zone lymphoma: a literature review of diagnostic and therapeutic challenges. Rev Bras Hematol Hemoter (2016) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Global epidemiology of hepatitis C virus infection. Lancet Infect Dis (2005) 16.44
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood (1997) 11.04
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med (1992) 8.06
Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med (2002) 7.52
Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis (2000) 6.54
Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med (2004) 4.47
Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst (2004) 4.07
Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood (2002) 2.57
Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood (2000) 2.39
Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol (2005) 2.12
The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia (1994) 2.11
Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood (2006) 2.06
Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. Gastroenterology (2003) 1.93
Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol (2008) 1.91
Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. J Clin Oncol (2005) 1.88
Cryoglobulins. J Clin Pathol (2002) 1.85
Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology (2006) 1.81
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol (2011) 1.81
Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa. Ann Oncol (2006) 1.71
Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood (2010) 1.64
Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia (2004) 1.62
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. Am J Hematol (2008) 1.57
MALT Lymphomas. Hematology Am Soc Hematol Educ Program (2001) 1.50
Deciphering leukemic B-cell chronic lymphoproliferative disorders. Leuk Lymphoma (2006) 1.46
Disappearance of gastric mucosa-associated lymphoid tissue in hepatitis C virus-positive patients after anti-hepatitis C virus therapy. J Clin Gastroenterol (2004) 1.44
Splenic B cell lymphoma with circulating villous lymphocytes: differential diagnosis of B cell leukaemias with large spleens. J Clin Pathol (1987) 1.40
Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood (2010) 1.39
Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood (2006) 1.38
Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood (2010) 1.37
No association between hepatitis C and B-cell lymphoma. Hepatology (1999) 1.28
Non-Hodgkin's lymphoma and hepatitis C virus: a case-control study from northern and southern Italy. Int J Cancer (2004) 1.27
How I treat indolent lymphoma. Blood (2007) 1.20
Clinical presentation and management of marginal zone lymphomas. Hematology Am Soc Hematol Educ Program (2005) 1.17
Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood (2004) 1.16
Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Hum Pathol (2000) 1.13
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol (2006) 1.09
Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol (2006) 1.08
Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma. J Hepatol (2008) 1.06
The histopathology of splenic lymphoma with villous lymphocytes. Blood (1994) 1.01
Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. Am J Pathol (2001) 0.99
Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med (2005) 0.99
Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. Aliment Pharmacol Ther (2005) 0.98
Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection. Br J Haematol (2004) 0.97
Treatment of HCV-related mantle-cell lymphoma with ribavirin and pegylated interferon Alfa. N Engl J Med (2003) 0.95
Characterization of B cell lymphoma in patients with Sjögren's syndrome and hepatitis C virus infection. Arthritis Rheum (2007) 0.93
The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood (2001) 0.91
Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. Br J Haematol (2007) 0.91
Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. Ann Oncol (2009) 0.91
Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. Oncologist (2006) 0.90
Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas. Br J Haematol (2009) 0.90
Long-lasting remission of primary hepatic lymphoma and hepatitis C virus infection achieved by the alpha-interferon treatment. Hematol J (2004) 0.89
Additional neoplasms and HCV infection in low-grade lymphoma of MALT type. Br J Haematol (1996) 0.88
Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia. Am J Hematol (2007) 0.87
Nongastric mucosa-associated lymphoid tissue lymphomas. Clin Lymphoma (2003) 0.86
Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma. Clin Lymphoma Myeloma Leuk (2011) 0.86
Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study. Clin Exp Rheumatol (2011) 0.86
Regression of advanced non-splenic marginal zone lymphoma after treatment of hepatitis C virus infection. Leuk Lymphoma (2005) 0.85
Advances in the treatment of hepatitis C virus infection. Gastroenterol Hepatol (N Y) (2012) 0.83
Frequency of bcl-2 rearrangement in patients with mixed cryoglobulinemia and HCV-positive liver diseases. Clin Exp Rheumatol (1998) 0.82
Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection. Int J Cancer (2009) 0.81
Splenic B cell lymphoma with "villous" lymphocytes in the peripheral blood: a disorder distinct from hairy cell leukemia. Leukemia (1987) 0.81
The relationship between splenic marginal zone B-cell lymphoma and chronic liver disease associated with hepatitis C virus infection. Ann Ital Med Int (2000) 0.80
Regression of B-cell lymphoma of the liver with hepatitis C virus infection after treatment with pegylated interferon-alpha and ribavirin. Dig Dis Sci (2009) 0.79
Marginal zone-related neoplasms of splenic and nodal origin. Haematologica (2003) 0.79
Clinical features and outcome in HCV-positive aggressive non-Hodgkin's lymphoma. Leuk Lymphoma (2003) 0.79
Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment. Br J Haematol (2001) 0.78
Splenic marginal zone B-cell lymphoma in a HIV-positive patient: a case report. Ann Hematol (2008) 0.78
[MALT lymphomas of the salivary glands. Review of the literature apropos of a case in a patient with hepatitis C virus infection]. Recenti Prog Med (1999) 0.78
An additional line of therapy with pegylated interferon and ribavirin after rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia and indolent non-Hodgkin's lymphoma previously treated with interferon. Blood Transfus (2011) 0.78
Systematic screening for HCV infection should be performed in patients with splenic marginal zone lymphoma. Br J Haematol (2004) 0.78
The association of hepatitis C virus infection with monoclonal rheumatoid factors bearing the WA cross-idiotype: implications for the etiopathogenesis and therapy of mixed cryoglobulinemia. Clin Exp Rheumatol (1996) 0.76
MALT non-Hodgkin's lymphoma associated with hepatitis C virus infection treated by interferon alpha. Am J Hematol (1996) 0.76
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med (2011) 4.50
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet (2009) 4.25
Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood (2003) 2.56
Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica (2002) 2.34
Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Blood (2013) 1.84
The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood (2009) 1.59
Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood (2012) 1.59
MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years. Neurology (2014) 1.58
Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum (2002) 1.48
Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors. Leuk Lymphoma (2013) 1.47
The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol (2006) 1.46
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. Blood (2013) 1.39
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood (2009) 1.36
Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome. Haematologica (2006) 1.32
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica (2013) 1.18
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. Haematologica (2010) 1.17
The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood (2011) 1.16
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N Engl J Med (2015) 1.15
Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol (2013) 1.10
Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer (2004) 1.08
Bone marrow assessment in asymptomatic immunoglobulin M monoclonal gammopathies. Br J Haematol (2014) 1.08
Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. Ther Drug Monit (2005) 1.02
Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica (2011) 1.02
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results. Eur J Haematol (2008) 1.01
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood (2002) 0.97
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol (2004) 0.97
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. Am J Hematol (2010) 0.97
Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol (2010) 0.96
Rituximab for the treatment of type II mixed cryoglobulinemia. Arthritis Rheum (2002) 0.96
Endogenous endophthalmitis following disseminated fungemia due to Fusarium solani in a patient with acute myeloid leukemia. Eur J Haematol (2002) 0.96
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood (2013) 0.95
Molecular lesions of signalling pathway genes in clonal B-cell lymphocytosis with marginal zone features. Br J Haematol (2014) 0.93
Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica (2012) 0.91
Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. Oncologist (2006) 0.90
Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol (2012) 0.89
CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. Blood (2013) 0.89
Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. Blood (2005) 0.89
Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL). Ann Hematol (2012) 0.88
Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia. Am J Hematol (2012) 0.88
Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer (2005) 0.88
Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica (2010) 0.88
Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires. Blood Cells Mol Dis (2009) 0.86
Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients. Br J Haematol (2010) 0.86
Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma. Clin Lymphoma Myeloma Leuk (2011) 0.86
High-resolution genome-wide array comparative genomic hybridization in splenic marginal zone B-cell lymphoma. Hum Pathol (2009) 0.86
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. Exp Hematol (2006) 0.86
Effect on survival of the development of late-onset non-infectious pulmonary complications after stem cell transplantation. Haematologica (2006) 0.85
Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia. Clin Transplant (2011) 0.84
Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use. Leuk Lymphoma (2013) 0.84
Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. Eur J Haematol (2010) 0.83
Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice. Am J Hematol (2013) 0.83
Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica (2013) 0.82
Bendamustine salvage therapy for T cell neoplasms. Ann Hematol (2013) 0.82
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma (2011) 0.81
Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection. Int J Cancer (2009) 0.81
Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol (2013) 0.81
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. Br J Haematol (2010) 0.80
Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab. Am J Hematol (2011) 0.80
The Risk of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia in Hodgkin Lymphoma has Substantially Decreased in the ABVD Era Abolishing Mechlorethamine and Procarbazine and Limiting Volumes and Doses of Radiotherapy. Mediterr J Hematol Infect Dis (2012) 0.79
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. Leuk Lymphoma (2009) 0.79
Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. Oncologist (2011) 0.79
Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. Br J Haematol (2012) 0.78
Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma. Am J Hematol (2015) 0.78
Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma (2014) 0.78
Looking for familial nodular lymphocyte-predominant Hodgkin lymphoma. Am J Hematol (2013) 0.78
Associated cancers in Waldenström macroglobulinemia: clues for common genetic predisposition. Clin Lymphoma Myeloma Leuk (2013) 0.78
Prognostic assessment in patients with indolent B-cell lymphomas. ScientificWorldJournal (2012) 0.78
MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. Blood (2013) 0.78
Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients. Haematologica (2003) 0.77
Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma. Am J Hematol (2015) 0.77
Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. Leuk Lymphoma (2014) 0.77
Central nervous system relapse occurs in about 5% of cases of acute promyelocytic leukaemia. Haematologica (2008) 0.77
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. J Hematol Oncol (2013) 0.76
Clinical predictors of outcome in MPN. Hematol Oncol Clin North Am (2012) 0.76
Antibiotic therapy-induced remission of bladder mucosa-associated lymphoid tissue (MALT) lymphoma carrying t(11;18)(q21;q21) apoptosis inhibitor 2-MALT1. J Clin Oncol (2013) 0.76
Rituximab maintenance in follicular lymphoma patients. World J Clin Oncol (2011) 0.75
Trisomy 8 in chronic lymphocytic leukemia: a report of two cases. Cancer Genet Cytogenet (2007) 0.75